BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/23/2021 1:30:21 PM | Browse: 521 | Download: 914
 |
Received |
|
2021-02-18 13:28 |
|
Peer-Review Started |
|
2021-02-18 13:33 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-03-16 22:25 |
|
Revised |
|
2021-03-25 10:58 |
|
Second Decision |
|
2021-05-07 13:38 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2021-05-07 14:12 |
|
Articles in Press |
|
2021-05-07 14:12 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2021-06-25 08:13 |
|
Typeset the Manuscript |
|
2021-07-21 11:58 |
|
Publish the Manuscript Online |
|
2021-07-23 13:30 |
| ISSN |
1948-0210 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Caecilia H C Sukowati, Korri Elvanita El-Khobar and Claudio Tiribelli |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| 2020 Grant of the Fondazione Umberto Veronesi, Milan, Italy (to Sukowati CHC) |
|
| Grant of the Regione Autonomo Friuli Venezia Giulia in Progetti Internazionali 2020 (DGR 2195 dd 20/12/2019) to the FIF |
|
|
| Corresponding Author |
Caecilia H C Sukowati, BSc, PhD, Senior Scientist, Centro Studi Fegato, Fondazione Italiana Fegato ONLUS, AREA Science Park Basovizza, SS14 km 163.5, Trieste 34149, Italy. caecilia.sukowati@fegato.it |
| Key Words |
Hepatocellular carcinoma; Programmed death-1; Programmed death ligand 1; Cancer stem cells; Cancer heterogeneity; Genetic variants |
| Core Tip |
Immune checkpoint inhibitors (ICIs), in particular the ICI against the programmed death-1/programmed death ligand 1 (PD-L1/PD-L1) axis, has been recently presented for the treatment of hepatocellular carcinoma (HCC). However, despite the success of anti-PD-1/PD-L1 in other cancers, a substantial proportion of HCC patients fails to respond. Here, we gather current information on biomarkers of anti-PD-1/PD-L1 treatment and the contribution of HCC heterogeneity and hepatic cancer stem cells. |
| Publish Date |
2021-07-23 13:30 |
| Citation |
Sukowati CHC, El-Khobar KE, Tiribelli C. Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells. World J Stem Cells 2021; 13(7): 795-824 |
| URL |
https://www.wjgnet.com/1948-0210/full/v13/i7/795.htm |
| DOI |
https://dx.doi.org/10.4252/wjsc.v13.i7.795 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
